John Volpone - 12 Aug 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: President
Issuer ticker: XFOR
Reported as of: 12 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2025, 20:31:46 UTC
Next SEC filing: 31 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian Bowersox, Attorney-In-Fact

Key filing fact

John Volpone filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 14 Aug 2025.

Key facts

This page summarizes John Volpone's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 20:31.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002081729 Primary reporting owner

Volpone John

Relationship: President
Address: C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON
Signature: /s/ Brian Bowersox, Attorney-In-Fact
Signature date: 14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +289,881
Change %
Price: $0.000000
Shares after: 289,881
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XFOR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,609,873
Change %
Price: $0.000000
Shares after: 1,609,873
Date: 12 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,609,873
Exercise price: $1.42
Footnotes: F2

XFOR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +529,201
Change %
Price: $0.000000
Shares after: 529,201
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 529,201
Exercise price: $3.14
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.

Footnote F2

One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.